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In Brief
NLRP3 inflammasome activation
contributes to chronic inflammation
associated with autoinflammatory
disease, yet understanding of NLRP3
inflammasome regulation is incomplete.
Hughes et al. show that the
deglutathionylating enzyme GSTO1-1
promotes NLRP3 inflammasome
activation through deglutathionylation of
NEK7. Furthermore, the GSTO1-1
inhibitor C1-27 reduces NLRP3
inflammasome activation in vitro and
in vivo.
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The NLRP3 inflammasome is a cytosolic complex
sensing phagocytosed material and various dam-
age-associated molecular patterns, triggering pro-
duction of the pro-inflammatory cytokines inter-
leukin-1 beta (IL)-1b and IL-18 and promoting
pyroptosis. Here, we characterize glutathione trans-
ferase omega 1-1 (GSTO1-1), a constitutive degluta-
thionylating enzyme, as a regulator of the NLRP3
inflammasome. Using a small molecule inhibitor
of GSTO1-1 termed C1-27, endogenous GSTO1-1
knockdown, and GSTO1-1/ mice, we report that
GSTO1-1 is involved in NLRP3 inflammasome activa-
tion. Mechanistically, GSTO1-1 deglutathionylates
cysteine 253 in NIMA related kinase 7 (NEK7) to pro-
mote NLRP3 activation. We therefore identify
GSTO1-1 as an NLRP3 inflammasome regulator,
which has potential as a drug target to limit NLRP3-
mediated inflammation.INTRODUCTION
The NLRP3 inflammasome is an intracellular pattern recognition
receptor (PRR) that is activated by phagocytosed particles or
agents such as ATP and mitochondrial DNA. Activation drives
oligomerization with the adaptor protein apoptosis-associatedC
This is an open access article under the CC BY-Nspeck-like protein containing a CARD (ASC), pro-caspase-1
(Martinon et al., 2002), and the recently described inflamma-
some component NEK7, a serine/threonine kinase that also
functions in mitosis (Shi et al., 2016b; He et al., 2016; Yissachar
et al., 2006; Sharif et al., 2019). Activation of the NLRP3 inflam-
masome results in processing of pro-interleukin-1 beta (pro-IL-
1b) and pro-IL-18 to mature cytokines and also triggers pyropto-
sis in macrophages (Fink and Cookson, 2006). These events are
highly inflammatory, and as a result NLRP3 is tightly regulated
post-translationally. NLRP3 phosphorylation in its pyrin domain
(PYD) limits inflammasome assembly (Stutz et al., 2017), as
does ubiquitination (Juliana et al., 2012).
Inflammatory insults can trigger oxidative dysfunction,
inducing reactive oxygen species (ROS) production to trigger
NLRP3 inflammasome activation (Zhou et al., 2011). NEK7 has
been recently identified as a ROS-sensing NLRP3 inflamma-
some component, requiring ROS for its phosphorylation and
subsequent interaction with NLRP3 (Shi et al., 2016b; Groß
et al., 2016), although the precise mechanism of how ROS af-
fects NEK7 is unknown. Further, chloride intracellular channel
(CLIC) family members drive NLRP3 inflammasome activation.
CLIC translocation triggers chloride and potassium (K+) efflux,
which promotes NEK7-NLRP3 interaction, events that are also
dependent on mitochondrial ROS (Domingo-Ferna´ndez et al.,
2017; Tang et al., 2017).
Glutathione (GSH) is the major non-protein tripeptide antioxi-
dant present within cells and can modify target cysteines via
glutathionylation and alter protein function (Hughes et al.,
2017; Ullevig et al., 2016; Zhang et al., 2017). Glutathioneell Reports 29, 151–161, October 1, 2019 ª 2019 The Authors. 151
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. C1-27 Limits NLRP3 Inflammasome Activation
(A) Inhibition of GSTO1-1-catalyzed 4-nitrophenacyl glutathione reduction by C1-27 dose dependently. The structure of C1-27 is displayed (n = 3).
(B and C) ELISA of IL-1b (B) and TNF-⍺ (C) in supernatants from BMDMs primed with 3 h LPS, incubated with 5 mM C1-27 for 45 min, and stimulated with 5 mM
ATP for 45 min (n = 3).
(D) Immunoblots corresponding to BMDMs treated as in (B) and (C) (n = 3).
(E and F) ELISA of IL-1b (E) and TNF-⍺ (F) in supernatants from BMDMs primed with LPS, incubated with 5 mMC1-27, and stimulated with 10 mM nigericin (n = 3).
(G) Immunoblot corresponding to BMDMs treated as in (E) and (F) (n = 3).
(H) Pyroptosis of BMDMs treated from (E) and (F) measured by secretion of lactate dehydrogenase (LDH) into the supernatant. % Cytotoxicity was calculated
relative to total lysis control of unstimulated cells (n = 3).
(I) Immunoblot of BMDMs pre-treated with 5 mM C1-27 and stimulated with LPS for indicated times (n = 3).
(legend continued on next page)
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transferase omega 1-1 (GSTO1-1) is a constitutively active de-
glutathionylating enzyme and has recently been implicated in
inflammatory macrophage activation downstream of TLR4
(Menon et al., 2014, 2017). GSTO1-1 has also been found in a
complex with ASC, a key inflammasome component (Coll
et al., 2011). We therefore examined a role for GSTO1-1 in
NLRP3 activation. We provide evidence for GSTO1-1 as a
regulator of the NLRP3 inflammasome and identify NEK7 as a
target. NEK7 must undergo deglutathionylation in order to be
active. Our findings suggest that the targeting of GSTO1-1 has
potential as a strategy to limit inflammation.
RESULTS
The GSTO1-1 Inhibitor C1-27 Limits NLRP3
Inflammasome Activation
To examine a role for GSTO1-1 in the NLRP3 inflammasome,
we used a recently described GSTO1-1 inhibitor, termed C1-27
(Ramkumar et al., 2016). ML175, a GSTO1-1 inhibitor that had
been used in previous studies, was found to be toxic on macro-
phages (Figures S1A and S1B). C1-27 potently inhibits GSTO1-
1, with a half maximal inhibitory concentration (IC50) of 44.5 nM
(Figure 1A). C1-27 dose-dependently blocked NLRP3 inflamma-
some stimulation when added after lipopolysaccharide (LPS)
priming and before ATP stimulation (Figure S1C), and a concen-
tration of 5 mM was selected for future experiments. Following
primingwith LPS, C1-27 inhibited ATP-stimulated NLRP3 activa-
tion, limiting IL-1b release (Figure 1B), with no effect on tumor
necrosis factor alpha (TNF-a) secretion (Figure 1C). Mature cas-
pase-1 p20 andmature IL-1b p17were also significantly reduced
by C1-27 (Figure 1D, supernatant panels, compare lane 7 to
lane 4). C1-27 treatment of LPS-primed bone-marrow-derived
macrophages (BMDMs) also limited IL-1b secretion in response
to nigericin stimulation (Figure 1E), with no difference in TNF-a
secretion (Figure 1F). Similar to ATP treatment, C1-27 reduced
mature caspase-1 p20 and mature IL-1b p17 secretion into the
supernatant (Figure 1G, supernatant panels, compare lane 7 to
lane 4). In addition, cell death mediated by nigericin-stimulated
inflammasome activation was significantly reduced by C1-27
treatment (Figure 1H). Similar to BMDMs, C1-27 significantly in-
hibited the release of IL-1b from human peripheral blood mono-
nuclear cells (PBMCs) (Figures S1D and S1E). Human PBMCs
produce IL-1b upon LPS stimulation alone, but this is increased
by addition of nigericin. C1-27 inhibited IL-1b release when
added before LPS stimulation (Figure S1D) but also when added
between LPS priming and nigericin stimulation (Figure S1E). To
assess if C1-27 was affecting TLR4 signaling, we examined the
phosphorylation of downstream activation markers of TLR4 ac-
tion. C1-27 pre-treatment did not limit degradation of IkBa (nu-
clear factor of kappa light polypeptide gene enhancer in B cells
inhibitor, alpha), nor did it limit phosphorylation of p38 and p65
(Figure 1I). We also assessed whether C1-27 treatment prior to
or post LPS priming would impact pro-IL-1b production in(J) Immunoblot of BMDMs treated with 5 mM C1-27 for 1 h before (lanes 1–3) or
(K and L) BMDMswere primedwith 100 ng/mL LPS for 4 h, treatedwith 5 mMC1-2
for IL-1b ELISA (K) or LDH release (L) (n = 3).
Data are mean ± SEM; p values calculated using one-way ANOVA with Sidak’sBMDMs. C1-27 pre-treatment reduced pro-IL-1b production in
BMDMs but not post-LPS treatment (Figure 1J). We next as-
sessed if C1-27 could limit non-canonical inflammasome
activation via transfected LPS (Kayagaki et al., 2011). C1-27
treatment prior to LPS transfection significantly reduced IL-1b
secretion (Figure 1K). C1-27 was unable to limit pyroptosis
associatedwith caspase-11 activation, anevent that isNLRP3 in-
dependent (Figure 1L), suggesting specificity toward NLRP3.We
therefore next examined whether C1-27 would inhibit AIM2 or
NLRC4 inflammasome activation. C1-27 pre-treatment prior to
poly (dA:dT) transfection was unable to limit IL-1b secretion (Fig-
ure S2A). C1-27 did not limit mature caspase-1 p20 or mature IL-
1b p17 secretion into the supernatant (Figure S2B, supernatant
panels, compare lane 7 to lane 4). We also assessed NLRC4 in-
flammasome activation. LPS-primed macrophages were pre-
treated with C1-27 prior to Salmonella typhimurium UK-1 infec-
tion. Similar to the AIM2 inflammasome, C1-27 did not reduce
IL-1b secretion in response to S. typhimurium (Figure S2C).
Both mature caspase-1 p20 and mature IL-1b p17 release were
also unaffected by C1-27 (Figure S2D, supernatant panels,
compare lane 7 to lane 4). GSTO1-1 has previously been identi-
fied as a target for cytokine release inhibitory drug (CRID) com-
pounds (Laliberte et al., 2003). A derivative of CRID3, termed
MCC950, is a potent NLRP3 inflammasome inhibitor (Coll et al.,
2015). Due to the similarities between C1-27 and MCC950, we
assessed if MCC950 could inhibit GSTO1-1 enzymatic activity.
MCC950 was a poor GSTO1-1 inhibitor, with an IC50 of
124.8 mM (Figure S2E). These data suggest that GSTO1-1 can
regulate theNLRP3 inflammasome by canonical and non-canon-
ical activators and is unlikely to be the target for MCC950 in the
NLRP3 inflammasome.
C1-27 Reduces ASC Speck Formation
Activation of the NLRP3 inflammasome results in oligomerization
of ASC through its PYD to form ASC specks (Lu et al., 2014), an
event upstream of caspase-1 activation. To gain insight into
the regulation of the NLRP3 inflammasome by GSTO1-1, we
assessed if C1-27 could reduce the formation of ASC
oligomers. Using disuccinimidyl suberate crosslinking, LPS
and ATP stimulation of BMDMs induced oligomerization of
ASC, detected in the Triton X-100 insoluble fraction by immuno-
blotting. Treatment with C1-27 prior to ATP stimulation reduced
ASC oligomerization (Figure 2A, Triton-insoluble panel, compare
lane 4 to lane 3). Monomeric ASC was also examined in the
Triton X-100 soluble fraction. In response to LPS and ATP,
ASC monomers were significantly depleted compared to C1-
27 treatment (Figure 2A, Triton-soluble panel, lane 3). ASC
monomers were more prominent in the C1-27-treated cells (Fig-
ure 2A, Triton-soluble panel, lane 4). ASC oligomerization was
also assessed by confocal microscopy, whereby ASC oligomers
form punctate specks (Masumoto et al., 1999; Sahillioglu et al.,
2014). BMDMs stimulated with LPS and ATP showed increased
presence of ASC specks (Figure 2B, third panel). Pre-treatmentafter (lanes 4–6) 4 h LPS treatment (lanes 1–3) (n = 3).
7 for 2 h, and transfected with 1 mg/mL LPS for 16 h. Supernatant was harvested
multiple comparisons test (**p < 0.01, ***p < 0.001).
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A C
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Figure 2. C1-27 Reduces ASC Speck
Formation
(A) BMDMs were primed with LPS for 3 h, incubated
with 5 mM C1-27 for 45 min, and stimulated with
5 mM ATP for 45 min. Cells were lysed in lysis buffer
containing Triton X-100. Triton X-100-insoluble
fraction was crosslinked using disuccinimidyl sub-
erate. Both the soluble and insoluble fractions were
analyzed by immunoblot for ASC expression (n = 3).
(B) Confocal microscopy analysis of ASC speck
formation in BMDMs. BMDMswere plated on sterile
12-mm cover glasses and stimulated as (A).
Following stimulation they were stained with rabbit
anti-ASC antibody and anti-rabbit Alexa Fluor 647
and ProLong Gold antifade reagent with DAPI. Im-
ages were acquired 320 magnification (n = 4).
(C) For quantification of ASC speck-positive cells, a
minimum of 11 random regions of interest for each
experimental condition across four independent
experiments were imaged and the number of ASC
speck-positive cells were counted (n = 4).
Data are mean ± SEM; p values calculated using
one-way ANOVA with Sidak’s multiple comparisons
test (***p < 0.001).with C1-27 reduced the level of ASC speck formation (Figure 2B,
fourth panel). These changes were quantified, demonstrating
that C1-27 significantly reduced the percentage of ASC speck-
positive cells (Figure 2C), thereby suggesting that GSTO1-1 is
involved in NLRP3 inflammasome assembly.
C1-27 Is Active In Vivo and Reduces Inflammasome
Activation Associated with DSS-Induced Colitis and
Experimental Autoimmune Encephalomyelitis
Mice deficient in NLRP3, caspase-1, and ASC have been found to
be highly sensitive to distal colon inflammation in the dextran so-
dium sulfate (DSS) model of inflammatory bowel disease
(Allen et al., 2010; Zaki et al., 2010). It was considered that the154 Cell Reports 29, 151–161, October 1, 2019lack of IL-18 processing led to a breakdown
in the intestinal barrier, resulting in the
escape of bacteria and an increase in
inflammation. We have previously found
that GSTO1-1-deficient mice are also sus-
ceptible to inflammation in the DSS model
(Menon et al., 2017). We therefore next
tested C1-27 in the DSS model and found
that C1-27 recapitulates the decreased
cytokine release observed in GSTO1-1/
mice. At day 8, GSTO1-1/ mice or mice
treated with C1-27 showed a significant
reduction in the levels of IL-18 in serum
and in the supernatant obtained from colon
slices cultured for 24 h (Figures 3A and
3B). Similar results were obtained for IL-1b
in colon culture supernatants (Figure 3C),
but the levels of IL-1b in serum were low
and not reliably detected in this study (<10
pg/mL; data not shown). To determine if
8-day treatment with C1-27 had a measur-able impact on GSTO1-1 activity, we determined the level of
GSTO1-1 activity in the liverwith the specific substrate 4-nitrophe-
nacyl glutathione (Board et al., 2008) (Figure 3D). GSTO1-1 activity
was absent from GSTO1-1/ mice and was significantly dimin-
ished in mice treated with C1-27. H&E photomicrographs from
the midsegment of mouse colons from control, C1-27-treated,
and GSTO1-1/ mice identified this region of the bowel with the
most intense active inflammation (Figure S3). GSTO1-1/ mice
exposed to DSS were associated with prominent submucosal
edema (Figure S3D, blue bracket). Wild-type (WT) mice exposed
toDSSwere injected daily with 50mg/kg C1-27, and they showed
more submucosal edemabut displayed similar levels of inflamma-
tory cell infiltrate compared with WT mice exposed to DSS alone
Figure 3. C1-27 Is Active In Vivo and
Reduces Inflammasome Activation Associ-
ated with DSS-Induced Colitis and EAE
Development
Mice were treated with azoxymethane (AOM)
7.5 mg/kg intraperitoneally (i.p.) at day 3. On day
0, DSS 2.5%was included in drinking water. C1-27
was introduced by daily i.p. injection at a dose of
50 mg/kg in 40% cyclodextrin from day 1 until
day 7. Mice were sacrificed and samples collected
on day 8.
(A) Serum IL-18 levels (n = 5–6).
(B) Colon culture supernatant IL-18 levels (n = 5–6).
(C) Colon culture supernatant IL-1b levels (n = 5–6).
(D) Liver GSTO1-1 activity with S-(4-nitrophenacyl)
glutathione (4NPG; n = 8–12).
(E) Clinical score after EAE induction of C57BL/6
mice injected daily with 40% cyclodextrin/PBS
vehicle control or 50 mg/kg C1-27 (n = 7).
(F) C57BL/6 mice treated in (E) were weighed daily.
Percentage weight was calculated from starting
weight of mice (n = 7).
Data are mean ± SEM; p values calculated using
Student’s t test or one-way ANOVA with Sidak’s
multiple comparisons test (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001).(FigureS3, compare FigureS3C to FigureS3B). The active chronic
inflammation caused thickening of the bowel in the DSS-treated
mice (Figure S3B). Inflammationwas seen in themucosa and sub-
mucosa and variably extended through the muscularis propria
(FiguresS3B–S3D). This supports the contention thatC1-27medi-
ates its effect on the release of IL-1b and IL-18 by modulating the
activity of GSTO1-1.
We next assessed if C1-27 could limit inflammation in the
NLRP3-dependent experimental autoimmune encephalomy-
elitis (EAE) model (Gris et al., 2010; Jha et al., 2010). Mice in-
jected daily with 50 mg/kg C1-27 had significantly delayed onset
of EAE and had an overall reduced clinical score (Figure 3E).
Further, mice injected with C1-27 maintained body weight
compared to vehicle controls (Figure 3F). These data support
that C1-27 is active in vivo and limits EAE induction.
GSTO1-1/ Mice Have Impaired NLRP3 Inflammasome
Activation
Wenext assessedwhethermacrophages fromGSTO1-1/mice
would also have impaired NLRP3 inflammasome activation.CellNo difference was observed in the expres-
sion of NLRP3 inflammasome compo-
nents in either unstimulated or LPS-
treated BMDMs compared to control
mice (Figure 4A). GSTO1-1 deficiency
was confirmed by immunoblotting (Fig-
ure 4A, fifth panel) and RNA expression
(Figure 4B). Peritoneal exudate cells
(PECs) from GSTO1-1/ mice confirmed
impairment of NLRP3 inflammasome acti-
vation in response to LPS and nigericin
treatment, with reduced release of maturecaspase-1 p20 and mature IL-1b p17 secretion into the superna-
tant (Figure 4C, supernatant panels, compare lane 6 to lane 3).
GSTO1-1/ PECs also had impaired IL-1b secretion confirmed
by ELISA (Figure 4D). GSTO1-1/ BMDMs exhibited reduced
NLRP3 inflammasome activation, with less mature caspase-1
p20 andmature IL-1b p17 detected in the supernatant (Figure 4E,
supernatant panels, compare lane 8 to lane 4). IL-1b secretion de-
tected by ELISA was also significantly reduced in GSTO1-1/
BMDMs (Figure 4F). Similar to C1-27, cell death resulting from
LPS and ATP stimulation was reduced in GSTO1-1/ BMDMs
(Figure 4G). We established that the inhibitory effect of GSTO1-
1 knockout was specific to the NLRP3 inflammasome as AIM2 in-
flammasome activation was unaffected in GSTO1-1/ BMDMs,
asmeasured by IL-1b release (Figure S4A) and caspase-1 and IL-
1b processing (Figure S4B, supernatant panels, compare lane 8
to lane 4). To confirm that the effect of C1-27 is due to inhibition
of GSTO1-1 during inflammasome activation, we added two con-
centrations of C1-27 to WT and GSTO1-1/ BMDMs. C1-27
significantly inhibited IL-1b release fromWT BMDMs but was un-
able to further reduce IL-1b release from GSTO1-1/ BMDMsReports 29, 151–161, October 1, 2019 155
Figure 4. GSTO1-1/ Mice Have Impaired
NLRP3 Inflammasome Activation
(A) Immunoblot of WT and GSTO1-1/ BMDMs
treated with 100 ng/mL LPS for 4 h (n = 3).
(B) qRT-PCR analysis of WT and GSTO1-1/
BMDMs primed with 100 ng/mL LPS for 4 h.
Samples were reverse transcribed and control (Ct)
values used for quantification relative to control
RPS18 gene (n = 3).
(C) Immunoblot of WT and GSTO1-1/ PECs
primed with 100 ng/mL LPS for 3 h and stimulated
with 10 mM nigericin for 45 min (n = 3).
(D) ELISA of IL-1b in the supernatants from PECs
treated in (C) (n = 3).
(E) Immunoblot of WT and GSTO1-1/ BMDMs
primed with 100 ng/mL LPS for 3 h and stimulated
with 10 mM nigericin for 45 min (n = 3).
(F) ELISA of IL-1b in the supernatants fromBMDMs
treated in (E) (n = 3).
(G) % Cytotoxicity from WT and GSTO1-1/
BMDMs primed with 100 ng/mL LPS for 3 h and
stimulated with 5 mM ATP for 45 min (n = 3).
(H) ELISA of IL-1b in the supernatants fromWT and
GSTO1-1/ BMDMs primed with 100 ng/mL LPS
for 3 h, treated with indicated doses of C1-27 for
45 min, and stimulated with 10 mM nigericin for
45 min (n = 3).
Data are mean ± SEM; p values calculated using
one-way ANOVA with Sidak’s multiple compari-
sons test (*p < 0.05, **p < 0.01).(Figure 4H), indicating that the effect of C1-27 was through inhibi-
tion of GSTO1-1. We also tested if endogenous knockdown of
GSTO1-1 in BMDMs would recapitulate the effects of C1-27
and GSTO1-1 deficiency on NLRP3 inflammasome inhibition. Us-
ing a small interferingRNA (siRNA)-mediated approach,GSTO1-1
was efficiently knocked down in BMDMs (Figures S4C and S4D,
second panel, compare lanes 5–8 to 1–4). In response to LPS and
ATP stimulation, GSTO1-1 knockdown cells had reduced mature
caspase-1 p20 and mature IL-1b p17 secretion into the superna-
tant (Figure S4D, supernatant panels, compare lane 8 to lane 4).
Reduced IL-1b secretion was also confirmed by ELISA156 Cell Reports 29, 151–161, October 1, 2019(Figure S4E). GSTO1-1 knockdown cells
exhibited normal responses to LPS,
including induction ofmRNA for IL-1b (Fig-
ure S4F), NLRP3 (Figure S4G), or the cyto-
kines IL-6 (Figure S4H) and TNF-a (Fig-
ure S4I). Overall, the use of the GSTO1-1
inhibitor C1-27, siRNA to GSTO1-1, and
GSTO1-1/macrophages indicate a reg-
ulatory role for GSTO1-1 in NLRP3 inflam-
masome activation.
NLRP3 Inflammasome Activation Is
Augmented in the Presence of
GSTO1-1 and Limited by Exogenous
GSH
We next assessed the functional role
for GSTO1-1 during NLRP3 inflamma-
some activation using a standard recon-stitution system in HEK293T cells (Shi et al., 2016a). Reconstitu-
tion of the NLRP3 inflammasome in the presence of GSTO1-1
significantly increased IL-1b secretion detected by ELISA (Fig-
ure 5A, compare histobar 3 to histobar 2). Overexpression of
GSTO1-1 did not alter expression of pro-caspase-1 (Figure 5B,
top panel). A role for GSTO1-1 suggests deglutathionylation as
a possible process required for NLRP3 activation. We therefore
next assessed if addition of exogenous GSH could limit NLRP3
inflammasome activation in BMDMs. Using a cell-permeable
ethyl-ester GSH (GSH-EE) (Anderson et al., 1985), added after
LPS priming, IL-1b secretion in response to LPS and ATP
Figure 5. GSTO1-1 Enhances NLRP3 Inflammasome Reconstitution
and NLRP3 Activation Is Limited by Exogenous GSH
(A) ELISA of IL-1b secreted by HEK293T cells transiently transfected with
plasmids encoding pro-caspase-1, pro-IL-1b, NLRP3, ASC, NEK7, and
GSTO1-1 and stimulated with 10 mM nigericin. DNA concentration was kept
constant using the relevant empty vector control (n = 3).
(B) Immunoblot of HEK293T cells transfected in (A) (n = 3).
(C) ELISA of IL-1b in the supernatants from BMDMs primed with LPS for 3 h,
incubated with GSH-EE (1 mM, 5 mM, or 10 mM) for 45 min, and stimulated
with 5 mM ATP for 45 min (n = 3).
(D) Immunoblot of BMDMs treated in (C) (n = 3).
Data are mean ± SEM; p values calculated using one-way ANOVAwith Sidak’s
multiple comparisons test (*p < 0.05, **p < 0.01).stimulation was significantly reduced (Figure 5C). GSH-EE dose-
dependently increased the levels of pro-IL-1b (Figure 5D, lysate
panel, compare lanes 4–6 to lane 3) and also reduced secretionof mature IL-1b p17 into the supernatant (Figure 5D, supernatant
panel, compare lanes 4–6 to lane 3).
GSTO1-1 Regulates the NLRP3 Inflammasome through
Deglutathionylation of NEK7 on Cysteine 253
The question arose as to how GSTO1-1 might be regulating the
NLRP3 inflammasome. NEK7 has been recently identified as an
NLRP3 inflammasome component, as it senses ROS to promote
NEK7-NLRP3 interaction (Shi et al., 2016b). We therefore exam-
ined if GSTO1-1might interact with NEK7. NEK7 co-immunopre-
cipitated with GSTO1-1 (Figure 6A, upper panel, compare
lane 3 to lane 1). An interaction with ASC was also observed
(lane 2). We were unable to detect an interaction between
GSTO1-1 and NLRP3 by immunoprecipitation (data not shown).
GSTO1-1 was unlikely to be regulating ASC, as ASC is utilized by
the AIM2 and NLRC4 inflammasomes and C1-27 did not limit
their activation. We therefore examined NEK7 as a potential
GSTO1-1 target. NEK7 is highly conserved between mouse
and human, with no variation in cysteine amino acid conserva-
tion (Figure S5, the asterisk denotes cysteine residues). Using
a specific antibody that recognizes the glutathionylation-gluta-
thione (SSG) motif, we found that NEK7 is a glutathionylated
protein as detected by immunoblotting (Figure 6B, upper panel,
lane 2). We next examined if GSTO1-1 and NEK7 could interact
endogenously. Using BMDMs, we identified an endogenous
interaction between NEK7 and GSTO1-1 during LPS and ATP
stimulation (Figure 6C, upper panel, lane 2). Endogenous immu-
noprecipitation of NEK7 from WT and GSTO1-1/ BMDMs and
subsequent immunoblotting for GSH revealed that NEK7 was
deglutathionylated upon LPS and ATP stimulation inWTBMDMs
(Figure 6D, upper panel, lane 3). In contrast, NEK7was still highly
glutathionylated upon LPS and ATP stimulation in GSTO1/
BMDMs (Figure 6D, upper panel, lane 7), suggesting that
GSTO1-1 is required for NEK7 deglutathionylation. To formally
evaluate the strength of the NEK7-GSTO1-1 interaction, we
performed direct binding studies using surface plasmon reso-
nance. WT GSTO1-1 exhibited moderate binding to NEK7 with
a disassociation constant (KD) of 60 ± 4 mM. Notably, mutation
of a catalytic cysteine (C32A) that enables GSTO1-1 mediated
deglutathionylation resulted in a 2-fold decrease in the binding
strength with a KD of 120.5 ± 0.25 mM (Figures 6E and 6F). This
suggests that C32 is involved in the interaction with NEK7,
possibly modulating its functional outcome.
To examine NEK7 cysteine glutathionylation, we overex-
pressed hemagglutinin (HA)-tagged NEK7 in HEK293T cells
and used mass spectrometry to identify GSH adducts. Tandem
mass spectrometry of immunoprecipitated NEK7 identified
NEK7 peptides with GSH adducts on cysteines 79 and 253
(Figures S6A and S6B). We next generated NEK7 cysteine to
alanine mutants by site-directed mutagenesis and reconstituted
the NLRP3 inflammasome using themutants to assess pro-IL-1b
processing. NEK7 mutants were adequately expressed in each
condition (Figure 6G). IL-1b secretion was comparable between
each cysteine to alanine mutant, with exception of NEK7 C253A,
which significantly enhanced IL-1b processing comparable to
WT NEK7 (Figure 6H, compare histobar 2 to histobar 1). These
data suggest that deglutathionylation of NEK7 on cysteine 253
might boost NEK7 function in relation to NLRP3 activation.Cell Reports 29, 151–161, October 1, 2019 157
Figure 6. NEK7 Deglutathionylation by
GSTO1-1 Promotes NLRP3 Activation
(A) Co-immunoprecipitation of HEK293T cells
transiently transfected with Myc-DDK-GSTO1-1,
HA-ASC, or HA-NEK7 plasmids. DNA concentra-
tion was kept constant using the relevant empty
vector control. Immunoprecipitated complexes
were analyzed by immunoblot (n = 3).
(B) Non-reducing immunoprecipitation of
HEK293T cells transiently transfected with HA-
NEK7 plasmid or relevant empty vector control.
Immunoprecipitated samples were harvested in
lysis buffer containing 50 mM N-ethylmaleimide,
and immunoprecipitated complexes were eluted
in sample buffer without DTT. Immunoprecipi-
tated samples were analyzed by immunoblot
(n = 3).
(C) Endogenous co-immunoprecipitation of NEK7
and GSTO1-1 from primary BMDMs. BMDMs
were primed with LPS for 3 h and stimulated with
5 mM ATP for 45 min. Immunoprecipitated com-
plexes were eluted using 5X sample loading buffer
(containing DTT) and analyzed by immunoblot. *
denotes non-specific band (n = 3).
(D) Endogenous non-reducing immunoprecipita-
tion of NEK7 from WT and GSTO1-1/ BMDMs
primed with 100 ng/ml LPS for 3 h and subse-
quently treated with 5 mM ATP for 15 min.
Immunoprecipitated samples were harvested in
lysis buffer containing 50 mM N-ethylmaleimide,
and immunoprecipitated complexes were eluted
in sample buffer without DTT. Immunoprecipi-
tated samples were analyzed by immunoblot
(n = 1).
(E and F) The affinity of NEK7-GSTO1-1WT (E) and
NEK7-GSTO1-1 C32A (F) interaction was deter-
mined by surface plasmon resonance by
measuring the graded concentration of GSTO1-1
(up to 300 mM). Top panel: binding of GSTO1-1
wild-type and mutant to the immobilized NEK7
presented as a response unit (RU) after subtrac-
tion from the reference flow cell. Bottom panel:
saturation plot curve for the respective in-
teractions (n = 4).
(G) Immunoblot of HEK293T cells transfected with
HA-NEK7 WT or HA-NEK7 cysteine to alanine
mutants. Samples were analyzed by immunoblot
using anti-HA antibody (n = 3). Densitometry was
performed using a representative blot.
(H) ELISA of IL-1b secreted into the supernatant of
HEK293T cells transiently transfected with NLRP3
inflammasome components, or NEK7 cysteine to alanine mutants and stimulated with 10 mM nigericin. DNA concentration was kept constant by addition of
relevant empty vector control (n = 3).
Data are mean ± SEM; p values calculated using one-way ANOVA with Sidak’s multiple comparisons test (***p < 0.001).Overall, our data point to a key role for the deglutathionylating
enzyme GSTO1-1 in the regulation of the NLRP3 inflammasome,
with NEK7 being a key target for deglutathionylation.
DISCUSSION
In this study, we provide evidence for GSTO1-1 as a regulator
of the NLRP3 inflammasome. It has previously been reported
that GSTO1-1/ mice produced less serum IL-1b in response
to in vivo LPS treatment (Menon et al., 2017), possibly pointing158 Cell Reports 29, 151–161, October 1, 2019to GSTO1-1 as an important NLRP3 regulator. In 2003, Lali-
berte et al. (2003) identified sulfonylurea-containing com-
pounds termed CRIDs as potential inhibitors of IL-1b secre-
tion. CRIDs were found to limit processing of IL-1b in human
monocytes, and mice given oral CRIDs had attenuated pro-
duction of IL-1b in response to LPS and ATP, with no effect
on IL-6 or TNF-a. Further analysis identified GSTO1-1 as a
potential CRID target by affinity labeling of GSTO1-1 with
radioactive CRID1 and CRID2. We initially hypothesized that
GSTO1-1 might be the target for MCC950, a derivative of
CRID2 (Coll et al., 2015), which we previously reported to be a
highly potent and selective NLRP3 inhibitor. We found that
MCC950 was a poor GSTO1-1 inhibitor, with an IC50 of
124.8 mM, compared to the more potent C1-27, which had
been found in an unbiased screen of GSTO1-1 inhibitors
(Ramkumar et al., 2016) and had an IC50 of 44.5nM. We there-
fore concluded that MCC950 was unlikely to be targeting
GSTO1-1 to regulate the NLRP3 inflammasome. However,
our evidence here implicates GSTO1-1 as an NLRP3 inflam-
masome regulator, limiting both canonical and non-canonical
inflammasome-mediated pro-IL-1b processing. Pre-treatment
with C1-27 also reduced pro-IL-1b expression in LPS-stimu-
lated BMDMs, which may be due to an additional inhibitory
effect occurring independently of nuclear factor kB (NF-kB)
activation. This effect was not replicated in GSTO1-1/
BMDMs. A previous study concerning MCC950 suggested
a lack of a role for GSTO1-1 in NLRP3 activation, as
GSTO1-1 knockdown in immortalized macrophages had no
effect on NLRP3 activation (Primiano et al., 2016). Our study,
however, using both GSTO1-1 knockdown and knockout
approaches implicate GSTO1-1 as an NLRP3 regulator. The
basis for this discrepancy is not clear but may perhaps
be due to the use of immortalized cells compared to primary
cells.
The question arose as to how GSTO1-1 might be regulating
the NLRP3 inflammasome. GSTO1-1 has a proinflammatory
function in vivo, as both C1-27-treated mice and GSTO1-
1/ mice showed decreased IL-18 and IL-1b secretion in a
DSS-induced colitis model of inflammation, although histolog-
ical staining actually identified increased neutrophil infiltration
and inflammation. Further, C1-27 reduced ASC speck forma-
tion, suggesting that GSTO1-1 functions upstream of cas-
pase-1 activation during inflammasome assembly. Due to
the observed lack of inhibition by C1-27 during AIM2 and
NLRC4 inflammasome activation, we hypothesized that
GSTO1-1 was regulating NLRP3 or NEK7 in a GSH-dependent
mechanism. GSTO1-1-deficient macrophages have increased
cellular glutathionylation, indicating GSTO1-1 serves as a de-
glutathionylating enzyme (Menon and Board, 2013). It should,
however, be mentioned that cells possess multiple glutathio-
nylation and deglutathionylation systems, such as the glutare-
doxin system, and the potential that these systems are also
contributing to inflammasome modulation cannot be ruled
out. Despite a previous finding identifying NLRP3 as a gluta-
thionylated protein (Guglielmo et al., 2017), we were unable
to detect glutathionylation of NLRP3 by immunoprecipitation
or mass spectrometry (data not shown). NEK7 was recently
identified as a ROS-sensing component of the NLRP3 inflam-
masome, as treatment of cells with N-acetylcysteine, a GSH
precursor, inhibited NEK7-NLRP3 interaction (Shi et al.,
2016b). Similarly, we found that pre-treatment with a cell-
permeable ethyl-ester form of GSH limited NLRP3 inflamma-
some activation. The kinase activity of NEK7 was dispensable
for NLRP3 inflammasome activation, indicating that NEK7
may act as a scaffold for inflammasome activation (Shi
et al., 2016b). Supporting this finding, oridonin, an inhibitor
of the NLRP3 NACHT domain on cysteine 279, was shown
to block NLRP3-NEK7 interaction, preventing NLRP3 inflam-masome assembly (He et al., 2018). Furthermore, cryo-elec-
tron microscopy revealed NEK7-NLRP3 interaction at 3.8 A˚
(Sharif et al., 2019). We found that NEK7 was glutathionylated
on cysteines 79 and 253 and that GSTO1-1 and NEK7 inter-
acted by overexpression, endogenously, and by surface plas-
mon resonance. As NEK7 and GSTO1-1 interacted more upon
inflammasome activation, NEK7 was deglutathionylated—this
did not occur in GSTO1-1/ BMDMs, where NEK7 remained
highly glutathionylated upon inflammasome activation, sug-
gesting that the deglutathionylation was indeed GSTO1-1
dependent. A previous report showed that caspase-1 is
glutathionylated, thereby limiting inflammasome activation
(Meissner et al., 2008). Our data indicate that NEK7 is also
glutathionylated, which similarly limits NLRP3 inflammasome
activation. Mutagenesis of C253 in NEK7 to alanine increased
IL-1b processing, indicating negative regulation of NEK7 by
C253 modification. Importantly, activation of the NLRP3 in-
flammasome was significantly enhanced in the presence of
GSTO1-1 by reconstitution, implicating GSTO1-1 as a regu-
lator of NLRP3 inflammasome activation.
Taken together, our data therefore identify GSTO1-1 as a
NLRP3 inflammasome regulator acting via deglutathionylation
of C253 in NEK7. Interestingly, neurological disorders, such as
Alzheimer’s disease, exhibit underlying oxidative imbalance.
The levels of GSH decrease as we age (Liu and Choi, 2000;
Saharan and Mandal, 2014), and pathological NLRP3 activa-
tion has recently been identified as a driver of Alzheimer’s dis-
ease (Heneka et al., 2013; Yin et al., 2018). Polymorphisms in
the gene encoding GSTO1-1 have been previously linked to
progression of Alzheimer’s disease (Li et al., 2003; Umlauf
et al., 2016). Targeting GSTO1-1 with agents such as C1-27
may have therapeutic benefits in limiting aberrant NLRP3 acti-
vation in neurological diseases such as Alzheimer’s disease
and multiple sclerosis (MS), indicated here from the inhibitory
effect of C1-27 on EAE. Development of novel GSTO1-1 inhib-
itors may hold promise in the treatment of NLRP3-mediated
inflammatory diseases.STAR+METHODS
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Anti-phospho-p65 Cell Signaling Cat# 93H1
Bacterial and Virus Strains
E.coli BL21(DE3) Novagen Cat# 69450
S. typhimurium UK-1 strain Dr. Sine´ad Corr, TCD N/A
Chemicals, Peptides, and Recombinant Proteins
ATP Invivogen Cat# tlrl-atpl
Nigericin Invivogen Cat# tlrl-nig
Poly (dA:dT) Invivogen Cat# tlrl-patn
C1-27 Prof. Nouri Neamati, University
of Michigan
N/A
Gentamicin Sigma Cat# G1397
GSH-EE Santa Cruz Cat# 118421-50-4
ProLong Gold antifade reagent with DAPI Biosciences Cat# P36931
Ultrapure rough LPS from E. coli, serotype
EH100
Alexis Cat# ALX-581-010-L001
HA peptide Sigma Cat# 116669750001
FuGENE HD Transfection Reagent Promega Cat# E2311
Strataclean Resin Agilent Technologies Cat# 400714
Dextran sulfate sodium salt (DSS) Colitis Grade MP Biomedicals Cat# 0216011010
S-(4-nitrophenacyl)glutathione Prof. Philip Board, ANU N/A
Disuccinimidyl suberate ThermoFisher Cat# 21655
Lipofectamine 2000 ThermoFisher Cat# 11668030
Lipofectamine RNAiMAX ThermoFisher Cat# 13778030
Critical Commercial Assays
Mouse IL-1b DuoSet ELISA R&D Systems Cat# DY401
Mouse TNFa DuoSet ELISA R&D Systems Cat# DY410
Human IL-1b DuoSet ELISA R&D Systems Cat# DY201
Mouse IL-1b Quantikine ELISA R&D Systems Cat# MLB00C
Mouse IL-1b ELISA kit Abcam Cat# ab216165
Cytotox 96 non-radioactive cytotoxicity assay Promega Cat# G1780
Quikchange II site directed mutagenesis kit Agilent Technologies Cat# 200521
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
HEK293T cells Sigma Cat# 12022001
J774.A1 cells Sigma Cat# 91051511
Experimental Models: Organisms/Strains
Mouse: C57BL/6J Harlan N/A
Mouse: GSTO1-1/ 129/SvEv-C57BL/6J Taconic Cat# TF1210
Oligonucleotides
Scramble siRNA ThermoFisher Cat# 43908430
GSTO1-1 siRNA ThermoFisher Cat# 4390771/s67153
Primer sequences, see Table S1 This paper N/A
Site directed mutagenesis sequences, see
Table S2
This paper N/A
Recombinant DNA
Myc-DDK-GSTO1-1 Origene Cat# pCMV6; MR202949
FLAG-NLRP3 Shi et al., 2016b Addgene; Cat# 75127
FLAG-Pro-Caspase-1 Shi et al., 2016b Addgene; Cat# 75128
HA-ASC Hornung et al., 2009 Addgene; Cat# 41553
FLAG-pro-IL-1b Shi et al., 2016b Addgene; Cat# 75131
HA-NEK7 Shi et al., 2016b Addgene; Cat# 75142
Software and Algorithms
Graphpad Prism 8.0 Graphpad https://www.graphpad.com/scientific-
software/prism/
Biacore 8000 BIAevaluation software GE Healthcare N/A
Mascot search engine Matrix Science http://www.matrixscience.comLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Professor
Luke O’Neill (laoneill@tcd.ie). Mutant plasmids were generated by site-directed mutagenesis, the sequences for which are available
in Table S2. All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
In vivo animal models
Animal details
All animal procedures were ethically approved by the Trinity College Dublin Animal Research Ethics Committee prior to experimen-
tation, and conformed with the Directive 2010/63/EU of the European Parliament.
Eight- to twelve-week old C57BL/6J (Harlan) and GSTO1-1/mice on the C57BL/6J background were bred under specific path-
ogen-free conditions at Trinity Biomedical Science Institute animal facility. For the DSS study, GSTO1-1/ 129/SvEv-C57BL/6J
mice were obtained from Taconic and were originally derived from 129S-5 ES cells and backcrossed to an albino C57BL/6J strain.
GSTO1-1/ and wild-type mice that had been backcrossed to C57BL/6J mice from Charles River were much less sensitive to DSS
and were not used in this study.
DSS-induced colitis model
Mice were treated with Azoxymethane (AOM) 7.5mg/kg ip.at day3. On day 0, DSS 2.5%was included in drinking water. C1-27 was
introduced by daily ip injection at a dose of 50mg/kg in 40% cyclodextrin from day1 until day 7. Mice were sacrificed and samples
collected on day 8.
Experimental autoimmune encephalomyelitis
To induce EAE, 6–8 week old female C57BL/6 mice received subcutaneous immunization with MOG35–55 peptide (150mg/mouse)
emulsified in complete Freund’s adjuvant containing 4mg/mL heat-killed MTB. Mice were injected intraperitoneally with
200ng/mouse pertussis toxin on day 0 and day 2. Mice were injected daily with 50mg/kg C1-27 (40% cyclodextrin/PBS) intraperi-
toneally. Mice were weighed daily during the trial. EAE disease scores were recorded as follows: grade 0, normal; grade 1, limp
tail; grade 2, wobbly gait; grade 3, hind limb weakness; grade 4, hind limb paralysis; and grade 5, tetraparalysis/death.Cell Reports 29, 151–161.e1–e5, October 1, 2019 e2
In vitro models
Culturing primary bone marrow-derived macrophages (BMDMs)
Bone marrow was obtained by flushing the femur, tibia and hip bone of adult mice with a 25-gauge needle. The bone marrow was
subsequently resuspended in red cell lysis buffer (Sigma) for 3minutes before being centrifuged, resuspended, and passed through a
100 mm cell strainer. Cells were cultured in non-tissue culture treated 10cm dishes for 6 days in DMEM supplemented with FCS
(10%), penicillin-streptomycin (1%) and L929 supernatant (10%). On day 6, cells were plated at 5x105 cells/mL unless otherwise
stated. Peritoneal exudate cells were isolated by peritoneal cavity lavage with sterile PBS.
Culturing HEK293T cells
Cells were cultured in DMEM supplemented with FCS (10%) and penicillin-streptomycin.
Culturing J774.A1 cells
Cells were cultured in DMEM supplemented with FCS (10%) and penicillin-streptomycin.
METHOD DETAILS
Inflammasome assays
BMDMswere seeded at 5x105 cells/mL on 12-well plates and left overnight at 37C in 5%CO2 incubator. Cells were treated with LPS
(100ng/mL) for 3h. After 3h,media was removed, cells washedwith PBS and replacedwith serum-free DMEM. TheGSTO1-1 inhibitor
C1-27was added for 45min at a concentration of 5 mMunless otherwise stated. Cells were treated with ATP (5mM) or 10 mMNigericin
(10 mM) for 45min for NLRP3 inflammasome activation. Poly (dA:dT) (1 mg) was transfected into cells for 2h using Lipofectamine 2000
for activation of the AIM2 inflammasome. To assess NLRC4 inflammasome activation, Salmonella typhimuriumUK1was grown in LB
broth at 37C shaking overnight, and subsequently sub-cultured until OD1. Bacterial innocula were prepared by centrifugation and
washed with PBS, followed by reconstitution in DMEM to M.O.I. 20 for an infection assay. On the day of the assay, BMDMs were
treated with LPS (100ng/mL) for 3h. Mediumwas removed and replaced with serum free DMEM containing C1-27 for 45min followed
by infectionwithS. typhimurium atM.O.I 20 for 15min. After 15min, gentamicin (50 mg/mL) was added to kill extracellular bacteria for a
further 90min. For all assays 500 mL of supernatant was collected and stored for ELISA. The remaining supernatant was incubated
with 5 mL of StrataClean Resin beads, briefly vortexed for 1min and centrifuged at 400 x g for 2 min at 4C. The supernatant was
removed, and beads were resuspended in 30 mL 5X sample loading buffer. Cells were lysed in 50 mL 5X sample loading buffer
and analyzed by SDS-PAGE.
LPS Transfection
BMDMswere seeded at 5x105 cells/mL on 12-well plates and left overnight at 37C in 5%CO2 incubator. Cells were treated with LPS
(100ng/mL) for 4h to induce caspase-11 expression. After 4h, medium was removed, and cells were washed with PBS. 1mL of com-
plete medium was added to cells. 2 mL of LPS (1mg/mL) was added to 45.5 mL Opti-MEMmedium and vortexed immediately. 2.5 mL
RT FuGENE HD transfection reagent was added to the LPS/Opti-MEM,mixed gently and left for 10min RT. 50 mL was added per well
and left for 16h before harvesting supernatant for ELISA and LDH assays.
LDH release assay
Supernatants harvested were assessed for LDH release following inflammasome activation. Lactate release was quantified using the
Cytotox 96 non-radioactive cytotoxicity assay (Promega) according to manufacturer’s instructions.
Immunoprecipitations
BMDMswere seeded at 1x106 cells/ml in 10cm dishes 12h-24h prior to treatment. HEK293T cells were seeded at 2.5x105 cells/mL in
10cm dishes for 24h-36h prior to transfection. In all cases, the amount of plasmid DNA was kept constant in each transfection by
using the appropriate amount of empty vector control. 24h post transfection cells were washed with 5mL ice-cold PBS before being
transferred directly to ice. Cells were harvested by lysis in 700 mL of low stringency lysis buffer (50mM HEPES pH 7.5, 100mM NaCl,
1mM EDTA, 10% glycerol, 0.5% Nonident P40 (NP-40), 1mM phenylmethylsulfonyl fluoride (PMSF), 11.5 mg/mL aprotinin, 1 mg/mL
leupeptin and 1mM sodium orthovanadate) for 15min on ice. For non-reducing immunoprecipitations, N-ethylmaleimide (50mM)
was added. Plates were scraped with a cell scraper and lysate transferred into microcentrifuge tubes. Tubes were centrifuged at
21380 x g for 10min at 4C. Microcentrifuge tubes were prepared with 30 mL A/G bead slurry with 1 mg of the relevant antibody or
IgG control. 650 mL of lysate was then incubated with antibody coated A/G beads for 2h rotating at 4C. The remaining 50 mL of lysate
was boiled with 10 mL 5X sample loading buffer with DTT. For non-reducing immunoprecipitations, DTT was omitted from sample
loading buffer. After 2h, IP samples were centrifuged at 400 x g for 2min at 4C, supernatant removed, and beads washed three times
with 1mL low stringency lysis buffer. The immune complexes were eluted by addition of 50 mL 5X sample loading buffer, boiled for
5min (reducing) or heated at 50C for 10min (non-reducing) and analyzed by SDS-PAGE.
RNA extraction and qPCR
Cell supernatant was removed, cells were washed with PBS and lysed in 350 mL lysis buffer (Ambion). The cell lysates were imme-
diately frozen at80C and thawed gently prior to RNA extraction. Upon thawing, one volume 70%EtOHwas added to allow for RNAe3 Cell Reports 29, 151–161.e1–e5, October 1, 2019
precipitation before transferring to Ambion RNA spin columns. The purification was followed as per manufacturer’s instructions. The
elutedRNAwas quantified using aNanodrop 2000micro-volumeUV-vis spectrophotometer and eachRNA samplewas diluted to the
lowest yield before reverse-transcriptase PCR.
Disuccinimidyl suberate crosslinking
BMDMswere seeded at 1.5x106 cells/mL in 6-well plates in technical duplicate and incubated at 37C 5%CO2 overnight. Cells were
pre-treated with LPS (100ng/mL) for 3h. After 3h of LPS stimulation, media was removed and replaced with 1mL DMEM containing
C1-27 for 45 min. After 45 min, cells were treated with ATP (5mM) for 45 min. Supernatant was removed and cells were washed twice
with 200 mL ice cold HEPES (50mM). Cells were lysed on ice for 15min in 200 mL lysis solution (0.5% Triton X-100, 50mM HEPES,
protease and phosphatase inhibitors). Duplicate samples were pooled and centrifuged at 6000 x g for 15 min at 4C. The
Triton X-100 soluble fraction (supernatant) was removed and stored at20C. The Triton X-100 insoluble fraction (pellet) waswashed
twice with HEPES (50mM) and centrifuged at 6000 x g for 15 min at 4C. During the washing step, disuccinimidyl suberate-cross-
linking buffer was made (50mM HEPES, 150mMNaCl pH 8). Disuccinimidyl suberate was allowed to reach RT prior to resuspension
in anhydrous DMSO (54.3 mL DMSO to 2mg disuccinimidyl suberate for 100mM stock). The Triton X-100 insoluble pellet was resus-
pended in 490 mL disuccinimidyl suberate-crosslinking buffer and incubated with 10 mL rehydrated disuccinimidyl suberate (2mM
final concentration), mixed immediately and incubated for 45min at 37C. After 45min, samples were centrifuged at 6000 x g for
15 min at 4C. The supernatant was removed gently, and the remaining disuccinimidyl suberate-crosslinked pellet was resuspended
in 50 mL sample loading buffer containing DTT. Samples were analyzed by SDS-PAGE.
Confocal Microscopy
BMDMs were plated in 24-well plates at a density of 1x105cells/mL on sterile 12mm cover glasses and left overnight at 37C in 5%
CO2 incubator. Cells were primed with LPS (100ng/mL) for 3h, medium removed and treated with C1-27 for 45min. ATP (5mM) was
added for 45min. Media was removed and cover glasses washed twice with PBS. Cells were fixed with 4% paraformaldehyde for
20min. Cover glasses were washed twice with PBS and permeabilized with 0.1%Triton X-100 for 25min. Cover glasseswere washed
twice with PBS and incubated with rabbit anti-ASC (1:100) overnight at 4C. Cover glasses were washed with PBS for 20min and
incubated with anti-rabbit Alexa Fluor 647 for 2h at RT. Cover glasses were washed twice with PBS for 20min, removed andmounted
on 3 mL ProLong Gold antifade reagent with DAPI. Cover glasses were sealed with clear nail polish overnight at RT. A minimum of
three images were taken from each sample for analysis. Images were acquired on a Leica SP8 scanning confocal microscope (Leica
Microsystems) at x 20 magnification. For quantification of ASC speck positive cells, a minimum of 11 random regions of interest for
each experimental condition were imaged and the number of ASC speck-positive cells were counted.
Colon organ culture
Colonic cytokine production was measured in supernatants from ex vivo organ culture. Distal colon segments (1 cm) were cut longi-
tudinally and washed in ice cold PBS with penicillin (50 mg/mL), streptomycin sulfate (50 mg/mL), and neomycin sulfate (100 mg/mL)
(Invitrogen). After washing, the wet weight of each sample was recorded. Each segment was cultured in 48-well culture plates with
350 mL serum-free RPMI-1640 medium supplemented with antibiotics for 24h in a humidified atmosphere of 5% CO2 at 37
C. The
supernatants were collected by centrifugation at 13,4003 g and 4C for 3 min to remove tissue debris and then stored at80C until
analyzed.
Histological Analysis
For histological analysis the colonwas opened longitudinally and fixed in 10%buffered formalin. A roll of the organ wasmade to allow
orientated histological assessment of the colon including the rectum. Following routine laboratory processing hematoxylin and eosin
stained sections of the paraffin embedded tissues were prepared. The tissue was analyzed by a specialist Anatomical Pathologist
(JED) in a blinded fashion. The criteria used for grading of inflammation have been previously described (Mladenova et al., 2011).
Criteria used to grade inflammation included the presence of inflammatory cells in themucosa and lamina propria, structural changes
in the crypt architecture and expansion of the lamina propria.
Endogenous knockdown of GSTO1-1
BMDMswere seeded at 5x105 cells/mL on 12-well plates and left overnight at 37C in 5%CO2 incubator. Cell mediumwas removed,
and cells were washed briefly with PBS. 500 mL Opti-MEM reduced serummediumwas added to cells. Scramble siRNA or GSTO1-1
siRNA was incubated with 5 mL RNAiMAX Lipofectamine reagent in 500 mL Opti-MEM for 10min. After incubation, 500 mL siRNA-lip-
ofectaminemix was added to cells to yield 1mL of Opti-MEMmedium containing 20nmol siRNA final concentration. Cells were left for
36h-48h before treatment.
NEK7 Expression and purification
The codon-optimized NEK7 gene construct was synthesized and cloned into pJ411KanR (ATUM). The construct was overexpressed as
an N-terminal His6 tag fusion protein in E. coli BL21(DE3) (Novagen) at 18
C following induction with 0.5 mM IPTG. The cells were
resuspended in sodium phosphate buffer (pH 7.0) (50 mM), NaCl (500 mM), 0.5% Triton X-100, b-ME (3 mM) and imidazole (BufferCell Reports 29, 151–161.e1–e5, October 1, 2019 e4
A) (30 mM) and lysed by French press (1500 psi). The lysate was cleared by centrifuging at 15000 rpm for 30 min and NEK7 was pu-
rified using a 5mLHisTrap column (GEHealthcare) in Buffer Awith up to 500mM imidazole gradient. To cleave the His-tag, the eluted
fractions were pooled and subjected to HRV3c protease digestion for overnight at 4C in buffer A. The His-tag cleaved NEK7 was
subsequently loaded and purified by passing through HisTrap column (GE Healthcare). The Ni-NTA purified NEK7 was dialysed
into sodium phosphate buffer (pH 7.0) (50mM), NaCl (150mM) and further purified by the size exclusion chromatography (SEC) tech-
nique using a superdex 200 increase 10/300 gel filtration column (GE Healthcare). Similarly, GSTO1-1 wild-type and mutant proteins
were expressed and purified as ubiquitin fusion proteins as previously described (Baker et al., 2005).
Surface plasmon resonance
Surface plasmon resonance (SPR) experiment was carried out at 25C on a Biacore 8000 instrument (GE healthcare) using HBS
buffer (10 mM HEPES-HCl, pH 7.4, and 150 mM NaCl) with EDTA (3 mM) and 0.05% P20 as a running buffer. The purified NEK7
was filtered and coupled (1500 RU) onto CM5 sensor chip (GE healthcare) through amine coupling. The affinity measurement
was performed by passing increasing concentrations of GSTO1-1 wild and mutant (up to 300 mM) at the flow rate of 5 mL/min.
The final response unit was calculated by subtracting the response obtained from the reference flow cell. The data were fitted using
the Biacore 8000 BIAevaluation software and GraphPad Prism Version 8.0 for data presentation.
Mass Spectrometry of NEK7
HEK293T cells were reverse transfected with HA-tagged NEK7. HEK293T cells were seeded at 7.5x105 cells/mL in 10mL in 10cm
dishes. During the plating, 10 mg NEK7 was transiently transfected into the HEK293T cells using GeneJuice and left overnight at
37C in 5% CO2 incubator. Cell medium was removed, cells were washed gently with PBS and cells were immediately lysed in
low stringency lysis buffer containing protease and phosphatase inhibitors. An immunoprecipitation was performed using an anti-
HA antibody conjugated to A/G beads. After 2h rotating at 4C, A/G beads were washed three times with low stringency lysis buffer.
After the third wash, the A/G beads were dried and incubated with 250 mL of 200 mg HA peptide or 30min at 37Cwith gentle shaking.
Beadswere agitated every 5min to prevent sedimentation of A/G beads. A/G beadswere centrifuged at 200 x g for 2min. Supernatant
was removed and stored on ice. A/G beads were subsequently incubated with a further 250 mL of 200 mg HA peptide for 30min at
37C at 300rpm and centrifuged at 400 x g for 2min. Both 250 mL supernatants were combined and concentrated using an Amicon
Ultra 10K concentrating column (Merck Millipore). The concentrated eluate was incubated with GSSG (5mM, pH 8) for 1h at RT prior
to loading on an 8% acrylamide gel. The 8% gel was fixed in Coomassie blue fixing solution (50%MeOH, 10%HoAC, 40% ultrapure
H2O) in a clear container for 30min on an orbital shaker at RT. Fixing solution was removed and replaced with Coomassie Blue R-250
for 1h at RT with gentle agitation. The gel was washed overnight at 4Cwith de-staining solution (5%MeOH, 7.5% HoAC and 87.5%
ultrapure H2O). The gel bands were excised in a laminar flow hood and placed in sterile eppendorfs. 500 mL band wash solution was
added (50% MeOH, 5% HoAC and 45% ultrapure H2O) to eppendorfs and mixed at 1300rpm at RT for 2h, with wash solution
changed every 30min to remove Coomassie stain. Gel bands were stored in 500 mL band wash solution on dry ice. Gel fragments
were digested using Trypsin and analyzed by 1D nLC-MS/MS by a 4000QTRAP mass spectrometer. The resulting data was pro-
cessed using the Mascot search engine with an ion cut score of 20.
NLRP3 Inflammasome Reconstitution in HEK293T cells
HEK293T cells were seeded at 2x105 cells/mL in 24-well plates and left overnight at 37C in 5% CO2 incubator. The following morn-
ing, cells were transfected with plasmids encoding NLRP3 inflammasome components (ASC, 20ng; pro-IL-1b, 200ng; NLRP3,
200ng; pro-caspase-1; 100ng, and NEK7, 200ng; or NEK7 mutants, 200ng) and 200ng GSTO1-1 using Lipofectamine 2000. DNA
concentration was kept constant by adding relevant EV control plasmid. Cells were left for 24h. After 24h, medium was replaced
and supernatant was harvested 6h after medium change. Nigericin (10 mM) was added 1h prior to harvest. IL-1b secretion was
analyzed by ELISA. This protocol was adapted from Shi et al. (2016a).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
All statistical analyses were carried out using GraphPad Prism 8 (GraphPad Inc.) software. A Student’s t test was used to compare
two groups affected by a single variable, whereas a one-way ANOVA followed by Sidak’s multiple comparisons test was used to
compare multiple groups. Details of the statistical test used and the n number (representing biological replicates) can be found in
the appropriate figure legend. All data are mean ± SEM. Differences were considered statistically significant at P values of
*p% 0.05. ** signifies a P value of% 0.01, *** signifies a P value of% 0.001, and **** signifies a P value of < 0.0001.
DATA AND CODE AVAILABILITY
The published article contains all datasets generated or analyzed during this study.e5 Cell Reports 29, 151–161.e1–e5, October 1, 2019
